PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30249062-9	2018	Results showed that treating with methotrexate could alleviate the inflammatory condition, downregulate the activation of NF-kappaB and NLRP3/Caspase-1 inflammatory pathways and reduce the level of related cytokines.	Methotrexate	34-46	NLR family pyrin domain containing 3	Homo sapiens	136-141	
30249062-12	2018	These findings indicated that methotrexate could inhibit the onset of inflammation in joint tissue by suppressing the activation of NF-kappaB and NLRP3/Caspase-1 pathways and regulating the inflammation related metabolic networks.	Methotrexate	30-42	NLR family pyrin domain containing 3	Homo sapiens	146-151	
28356883-4	2016	METHODS: A group of 128 RA patients treated with methotrexate and 122 healthy controls were genotyped for NLRP3 rs35829419 (p. Q705K) and CARD8 rs2043211 (p. C10X) polymorphisms.	Methotrexate	49-61	NLR family pyrin domain containing 3	Homo sapiens	106-111	
15231984-0	2004	A novel CIAS1 mutation and plasma/cerebrospinal fluid cytokine profile in a German patient with neonatal-onset multisystem inflammatory disease responsive to methotrexate therapy.	Methotrexate	158-170	NLR family pyrin domain containing 3	Homo sapiens	8-13